BIIB 022

Drug Profile

BIIB 022

Alternative Names: Anti-IGF-1R monoclonal antibody - Biogen; BIIB-022

Latest Information Update: 29 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Hepatocellular carcinoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 22 Jan 2016 Dyax has been acquired by and merged into Shire
  • 29 Sep 2011 Biogen Idec completes a phase I trial in Non-small cell lung cancer (first-line therapy, combination therapy) in US (NCT00970580)
  • 29 Sep 2011 Biogen completes a phase I trial in Hepatocellular carcinoma in USA, Singapore, Taiwan and UK (NCT00956436)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top